A dose-finding study of duloxetine based on serotonin transporter occupancy

Psychopharmacology
Akihiro TakanoTetsuya Suhara

Abstract

Positron emission tomography (PET) has been utilized for determining the dosage of antipsychotic drugs. To evaluate the dosage of antidepressants such as selective serotonin reuptake inhibitors, serotonin transporter occupancy (5-HTT) is also a useful index. We investigated the degree of 5-HTT occupancy with different doses of the antidepressant duloxetine and the time-course of 5-HTT occupancy using PET. PET scans with [11C]DASB were performed before and after a single administration of duloxetine (5-60 mg), and three consecutive scans were performed after a single dose or repeated doses of 60 mg of duloxetine. 5-HTT occupancies by duloxetine were increased by 35.3 to 86.5% with dose and plasma concentration increments. The ED50 value of 5-HTT occupancy was 7.9 mg for dose and 3.7 ng/ml for plasma concentration. In the time-course of 5-HTT occupancy, mean occupancies were 81.8% at 6 h, 71.9% at 25 h, and 44.9% at 53 h after a single administration, and 84.3% at 6 h, 71.9% at 49 h, and 47.1% at 78 h after repeated administrations. Based on 5-HTT occupancy, 40 mg and more of duloxetine was needed to attain 80% occupancy, and 60 mg of duloxetine could maintain a high level of 5-HTT occupancy with a once-a-day administration sched...Continue Reading

References

Nov 1, 2000·Nuclear Medicine and Biology·A A WilsonS Houle
Apr 3, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J E TurcotteP Blier
Oct 2, 2001·Journal of Affective Disorders·A Yýldýz, G S Sachs
Nov 10, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·N GinovartS Houle
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Mar 29, 2002·Molecular Psychiatry·Johannes TauscherS Kapur
Apr 3, 2002·The Journal of Clinical Psychiatry·David J GoldsteinMark A Demitrack
May 10, 2002·The Journal of Clinical Psychiatry·Michael J DetkeMark A Demitrack
Aug 10, 2002·NeuroImage·Fumihiko YasunoHinako Toyama
Oct 24, 2002·Journal of Psychiatric Research·Michael J DetkeMark A Demitrack
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stephan A ChalonWilliam Z Potter
Sep 16, 2003·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Masanori IchiseRichard E Carson
Oct 27, 2004·Journal of Psychiatric Research·Stephen K BrannanAlan F Schatzberg
Dec 14, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael J DetkeIstvan Bitter
Dec 14, 2004·Journal of Psychiatric Research·Stephen K BrannanGary D Tollefson
Jan 11, 2005·The International Journal of Neuropsychopharmacology·Akihiro Takano, Tetsuya Suhara
Nov 18, 2005·The International Journal of Neuropsychopharmacology·Akihiro TakanoYoshiro Okubo

❮ Previous
Next ❯

Citations

Oct 24, 2012·Psychopharmacology·Akihiro TakanoLars Farde
Oct 3, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Henricus G RuhéAart H Schene
Oct 7, 2008·Clinical Neuropharmacology·Susanne EnglischMathias Zink
Apr 15, 2008·International Clinical Psychopharmacology·Madhukar H TrivediMichael J Detke
Dec 15, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Ryohei Matsumoto, Tetsuya Suhara
Jun 24, 2010·Journal of Psychiatry & Neuroscience : JPN·Pierre Blier
Mar 10, 2011·Journal of Pain Research·Alan WrightChad Vandenberg
Jun 23, 2009·Drugs·Monique P Curran
Jun 2, 2009·CNS Drugs·Natalie J Carter, Paul L McCormack
Mar 4, 2011·Clinical Pharmacokinetics·Mary Pat KnadlerRichard Bergstrom
Dec 3, 2013·Expert Opinion on Therapeutic Patents·Liming ShaoHong Yin
Mar 6, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·N R MirzaK B Troelsen
Oct 6, 2015·Journal of Affective Disorders·Michael PaulzenSarah E Lammertz
Nov 29, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Jeffrey S Stehouwer, Mark M Goodman
Jun 16, 2011·Medicinal Research Reviews·Louise M PatersonGitte M Knudsen
Aug 1, 2007·Expert Opinion on Therapeutic Patents·Yiyun Huang, Wendol A Williams
Dec 19, 2014·The International Journal of Neuropsychopharmacology·Jacqueline A M SmithS T Patil
Apr 1, 2011·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Mizuho SekineTetsuya Suhara
Sep 16, 2009·The International Journal of Neuropsychopharmacology·Ariel Graff-GuerreroShitij Kapur
Jan 16, 2014·The International Journal of Neuropsychopharmacology·Kohei OgawaYoshiro Okubo
Aug 7, 2009·The International Journal of Neuropsychopharmacology·Michael PaulzenGerhard Gründer
Oct 24, 2012·The International Journal of Neuropsychopharmacology·Cécile BétryNasser Haddjeri
Aug 16, 2016·European Journal of Nuclear Medicine and Molecular Imaging·Akihiro TakanoChrister Halldin
Oct 16, 2014·Journal of Psychopharmacology·Roger M Lane
Jul 7, 2012·Journal of Psychopharmacology·Daniel Zigman, Pierre Blier
Oct 14, 2010·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Sergio AbanadesRoger N Gunn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here